am 251 and am 1241

am 251 has been researched along with am 1241 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brogi, S; Corelli, F; Di Marzo, V; Ligresti, A; Mugnaini, C; Pasquini, S; Tafi, A1
Deng, H; Ibrahim, MM; Liu, Q; Makriyannis, A; Malan, PT; Mata, HP; Porreca, F; Vanderah, T1
McMahon, LR1
Baamonde, A; Curto-Reyes, V; Hidalgo, A; Llames, S; Menéndez, L1
Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV1

Other Studies

5 other study(ies) available for am 251 and am 1241

ArticleYear
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Quinolones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Recombinant Proteins; Stereoisomerism

2011
CB2 cannabinoid receptor-mediated peripheral antinociception.
    Pain, 2001, Volume: 93, Issue:3

    Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Indoles; Male; Morpholines; Naphthalenes; Pain Measurement; Peripheral Nervous System; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug

2001
Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, Local; Animals; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cocaine; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Ketamine; Macaca mulatta; Male; Midazolam; Morphine; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2

2006
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
    British journal of pharmacology, 2010, Volume: 160, Issue:3

    Topics: Analgesics; Animals; Bone Neoplasms; Camphanes; Cannabinoids; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Ganglia, Spinal; Humans; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Naloxone; Osteosarcoma; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB2; Spinal Cord

2010
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
    Journal of neuroimmunology, 2012, Volume: 244, Issue:1-2

    Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoids; Hyperalgesia; Indoles; Inflammation; Interleukin-1beta; Male; Morphine; Neuroglia; Pain; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Spinal Cord; Tumor Necrosis Factor-alpha

2012
chemdatabank.com